Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization

NCT03438682 — Completed, 89203 participants, Yale University
ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  
RegistryNCT03438682
StatusCompleted
Study typeObservational
Enrollment89203 (Actual)
SponsorYale University (Other); collaborators: University of California, Davis, National Center for Health Research, Patient-Centered Outcomes Research Institute, Food and Drug Administration (FDA)
ConditionsSterility, Female, Contraception, Contraceptive Device; Complications
InterventionsEssure, Laparoscopic sterilization, Intrauterine Device (IUD) (Device, procedure)
Datesstart 2018-09-30, primary completion 2021-07-31, completion 2021-07-31, first posted 2018-02-20, last updated 2021-11-03
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Sterility, Female All trials for Contraception All trials of Essure All trials of Laparoscopic sterilization

-Summary

More than 345,000 U.S. women undergo either tubal ligation ("getting her tubes tied") or Essure procedures each year to permanently avoid pregnancy. Both prevent pregnancy by blocking women's Fallopian tubes but neither are 100% effective. Both can have complications, but not enough is known to help women make an informed choice between the two.

Essure is popular because it can be performed without anesthesia in a doctor's office and women can return to work the next day. However, patients have reported that the Essure procedure was unexpectedly painful. Also, women need to use other contraceptives for 3 months and then return for testing, to make sure their tubes are blocked and will prevent pregnancy. Not all women return for this test and some may get pregnant before realizing their Essure didn't work.

Essure was approved by the Food and Drug Administration (FDA) in 2002, but no studies ever compared it to tubal ligation. By 2015, over 9,000 women reported serious complications to the FDA. Women who were unhappy with Essure found each other online and created a Facebook "Essure Problems" support group that now has over 31,000 members. After an FDA Advisory Board expressed concerns about Essure's risks, in 2016 the FDA required stronger warnings about complications and announced that "more rigorous research" was needed, demanding Essure's maker conduct a new study comparing the benefits and risks of Essure to tubal ligation. Unfortunately, that study will not be finished before September 2023.

To provide answers as rapidly as possible for women considering sterilization, we will analyze data from the medical records of thousands of women with sterilization procedures funded by California's Medicaid. As poor women and women of color have different experiences with healthcare, and they more often choose sterilization, comparing these women's experiences with Essure and tubal ligation is very important. We will compare the safety and effectiveness of the 2 sterilization procedures to answer:

* How many women got pregnant afterwards?
* How many operations did each woman need to become infertile?
* Which complications did women have (i.e. chronic pain, depression)? We will also check whether certain women (such as certain age groups or those with diabetes) were most likely to have problems after either procedure.

Expand all sections  ·  Collapse all

+Detailed description

Study Aims:

Aim 1. To compare the real world effectiveness of hysteroscopic sterilization, laparoscopic sterilization and intrauterine devices (IUDs) by calculating:

1. Pregnancy rates at 3, 6, 12, 24, 36, 48, and 60 months post-procedure, indicating sterilization failure.
2. Patient's ability to rely on sterilization after hysteroscopic sterilization (blocked tubes on hysterosalpingogram) compared to laparoscopic sterilization and IUDs at 3, 6, 12, 24, 36, 48, and 60 months post-procedure, indicating concern of sterilization failure.

Aim 2. To compare safety and complications after hysteroscopic sterilization laparoscopic sterilization, and IUD placement by:

1. Evaluating rates of reoperation to achieve sterilization or reinsertion to achieve IUD placement at 3, 6, 12, 24, 36, 48, and 60 months post-procedure.
2. Evaluating other outcomes suggested by patient partners, including additional surgeries due to complications, chronic pain, and/or depression, by measuring claims for narcotic prescriptions, and antidepressants at 3, 6, 12, 24, 36, 48, 60 months post-procedure (hysteroscopic sterilization, laparoscopic sterilization, or IUD placement).
3. Identify sociodemographic and pre-sterilization clinical variables which may predict complications following hysteroscopic sterilization compared to laparoscopic sterilization and to IUDs.

+Arms and interventions

ArmTypeInterventionsDescription
Essure Hysteroscopic SterilizationDevice: EssureWomen who have undergone Essure hysteroscopic sterilization
Laparoscopic SterilizationProcedure: Laparoscopic sterilizationWomen who have undergone laparoscopic sterilization
Intrauterine device (IUD) placementDevice: Intrauterine Device (IUD)Women who have undergone IUD placement
  • Essure (Device): Essure hysteroscopic sterilization
  • Laparoscopic sterilization (Procedure): Laparoscopic sterilization via electrocautery, ring, or clip.
  • Intrauterine Device (IUD) (Device): Intrauterine Device (IUD)

+Outcome measures

Primary outcomes

  • Effectiveness of hysteroscopic compared to laparoscopic sterilization and IUD placement (Aim 1a) [Pregnancy rates at 3 months post-procedure]: Pregnancy after sterilization or IUD placement, indicating failure
  • Effectiveness of hysteroscopic compared to laparoscopic sterilization and IUD placement (Aim 1a) [Pregnancy rates at 6 months post-procedure]: Pregnancy after sterilization or IUD placement, indicating failure
  • Effectiveness of hysteroscopic compared to laparoscopic sterilization and IUD placement (Aim 1a) [Pregnancy rates at 12 months post-procedure]: Pregnancy after sterilization or IUD placement, indicating failure
  • Effectiveness of hysteroscopic compared to laparoscopic sterilization and IUD placement (Aim 1a) [Pregnancy rates at 24 months post-procedure]: Pregnancy after sterilization or IUD placement, indicating failure
  • Effectiveness of hysteroscopic compared to laparoscopic sterilization and IUD placement (Aim 1a) [Pregnancy rates at 36 months post-procedure]: Pregnancy after sterilization or IUD placement, indicating failure
  • Effectiveness of hysteroscopic compared to laparoscopic sterilization and IUD placement (Aim 1a) [Pregnancy rates at 48 months post-procedure]: Pregnancy after sterilization or IUD placement, indicating failure
  • Effectiveness of hysteroscopic compared to laparoscopic sterilization and IUD placement (Aim 1a) [Pregnancy rates at 60 months post-procedure]: Pregnancy after sterilization or IUD placement, indicating failure

Secondary outcomes

  • Blocked fallopian tubes on post-procedure hysterosalpingogram test (Aim 1b) [3 months post-procedure]: Ability to rely on sterilization after hysteroscopic sterilization (assessed by having blocked tubes on post-procedure hysterosalpingogram test) compared to laparoscopic sterilization and IUDs
  • Blocked fallopian tubes on post-procedure hysterosalpingogram test (Aim 1b) [6 months post-procedure]: Ability to rely on sterilization after hysteroscopic sterilization (assessed by having blocked tubes on post-procedure hysterosalpingogram test) compared to laparoscopic sterilization and IUDs
  • Blocked fallopian tubes on post-procedure hysterosalpingogram test (Aim 1b) [12 months post-procedure]: Ability to rely on sterilization after hysteroscopic sterilization (assessed by having blocked tubes on post-procedure hysterosalpingogram test) compared to laparoscopic sterilization and IUDs
  • Blocked fallopian tubes on post-procedure hysterosalpingogram test (Aim 1b) [24 months post-procedure]: Ability to rely on sterilization after hysteroscopic sterilization (assessed by having blocked tubes on post-procedure hysterosalpingogram test) compared to laparoscopic sterilization and IUDs
  • Blocked fallopian tubes on post-procedure hysterosalpingogram test (Aim 1b) [36 months post-procedure]: Ability to rely on sterilization after hysteroscopic sterilization (assessed by having blocked tubes on post-procedure hysterosalpingogram test) compared to laparoscopic sterilization and IUDs
  • Blocked fallopian tubes on post-procedure hysterosalpingogram test (Aim 1b) [48 months post-procedure]: Ability to rely on sterilization after hysteroscopic sterilization (assessed by having blocked tubes on post-procedure hysterosalpingogram test) compared to laparoscopic sterilization and IUDs
  • Blocked fallopian tubes on post-procedure hysterosalpingogram test (Aim 1b) [60 months post-procedure]: Ability to rely on sterilization after hysteroscopic sterilization (assessed by having blocked tubes on post-procedure hysterosalpingogram test) compared to laparoscopic sterilization and IUDs
  • Reoperation to achieve sterilization or reinsertion to achieve IUD placement [3 months post-procedure]: Evaluating rates of reoperation to achieve sterilization or reinsertion to achieve IUD placement
  • Reoperation to achieve sterilization or reinsertion to achieve IUD placement [6 months post-procedure]: Evaluating rates of reoperation to achieve sterilization or reinsertion to achieve IUD placement
  • Reoperation to achieve sterilization or reinsertion to achieve IUD placement [12 months post-procedure]: Evaluating rates of reoperation to achieve sterilization or reinsertion to achieve IUD placement
  • Reoperation to achieve sterilization or reinsertion to achieve IUD placement [24 months post-procedure]: Evaluating rates of reoperation to achieve sterilization or reinsertion to achieve IUD placement
  • Reoperation to achieve sterilization or reinsertion to achieve IUD placement [36 months post-procedure]: Evaluating rates of reoperation to achieve sterilization or reinsertion to achieve IUD placement
  • Reoperation to achieve sterilization or reinsertion to achieve IUD placement [48 months post-procedure]: Evaluating rates of reoperation to achieve sterilization or reinsertion to achieve IUD placement
  • Reoperation to achieve sterilization or reinsertion to achieve IUD placement [60 months post-procedure]: Evaluating rates of reoperation to achieve sterilization or reinsertion to achieve IUD placement
  • Need for subsequent surgery to remove foreign body, remove fallopian tube(s) (salpingectomy), or uterus (hysterectomy) [3 months post-procedure]: Need for surgical procedure after hysteroscopic or laparoscopic sterilization or IUD placement as assessed by surgery to remove foreign body, salpingectomy, or hysterectomy
  • Need for subsequent surgery to remove foreign body, remove fallopian tube(s) (salpingectomy), or uterus (hysterectomy) [6 months post-procedure]: Need for surgical procedure after hysteroscopic or laparoscopic sterilization or IUD placement as assessed by surgery to remove foreign body, salpingectomy, or hysterectomy
  • Need for subsequent surgery to remove foreign body, remove fallopian tube(s) (salpingectomy), or uterus (hysterectomy) [12 months post-procedure]: Need for surgical procedure after hysteroscopic or laparoscopic sterilization or IUD placement as assessed by surgery to remove foreign body, salpingectomy, or hysterectomy
  • Need for subsequent surgery to remove foreign body, remove fallopian tube(s) (salpingectomy), or uterus (hysterectomy) [24 months post-procedure]: Need for surgical procedure after hysteroscopic or laparoscopic sterilization or IUD placement as assessed by surgery to remove foreign body, salpingectomy, or hysterectomy
  • Need for subsequent surgery to remove foreign body, remove fallopian tube(s) (salpingectomy), or uterus (hysterectomy) [36 months post-procedure]: Need for surgical procedure after hysteroscopic or laparoscopic sterilization or IUD placement as assessed by surgery to remove foreign body, salpingectomy, or hysterectomy
  • Need for subsequent surgery to remove foreign body, remove fallopian tube(s) (salpingectomy), or uterus (hysterectomy) [48 months post-procedure]: Need for surgical procedure after hysteroscopic or laparoscopic sterilization or IUD placement as assessed by surgery to remove foreign body, salpingectomy, or hysterectomy
  • Need for subsequent surgery to remove foreign body, remove fallopian tube(s) (salpingectomy), or uterus (hysterectomy) [60 months post-procedure]: Need for surgical procedure after hysteroscopic or laparoscopic sterilization or IUD placement as assessed by surgery to remove foreign body, salpingectomy, or hysterectomy
  • Number of participants with new onset chronic pain as assessed by new prescriptions for narcotics [3 months post-procedure]: New prescription for narcotics after hysteroscopic compared to laparoscopic sterilization and IUD placement
  • Number of participants with new onset chronic pain as assessed by new prescriptions for narcotics [6 months post-procedure]: New prescription for narcotics after hysteroscopic compared to laparoscopic sterilization and IUD placement
  • Number of participants with new onset chronic pain as assessed by new prescriptions for narcotics [12 months post-procedure]: New prescription for narcotics after hysteroscopic compared to laparoscopic sterilization and IUD placement
  • Number of participants with new onset chronic pain as assessed by new prescriptions for narcotics [24 months post-procedure]: New prescription for narcotics after hysteroscopic compared to laparoscopic sterilization and IUD placement
  • Number of participants with new onset chronic pain as assessed by new prescriptions for narcotics [36 months post-procedure]: New prescription for narcotics after hysteroscopic compared to laparoscopic sterilization and IUD placement
  • Number of participants with new onset chronic pain as assessed by new prescriptions for narcotics [48 months post-procedure]: New prescription for narcotics after hysteroscopic compared to laparoscopic sterilization and IUD placement
  • Number of participants with new onset chronic pain as assessed by new prescriptions for narcotics [60 months post-procedure]: New prescription for narcotics after hysteroscopic compared to laparoscopic sterilization and IUD placement
  • Number of participants with new onset depression as assessed by new prescriptions for antidepressants [3 months post-procedure]: New prescription for anti-depressant medication after hysteroscopic compared to laparoscopic sterilization and IUD placement
  • Number of participants with new onset depression as assessed by new prescriptions for antidepressants [6 months post-procedure]: New prescription for anti-depressant medication after hysteroscopic compared to laparoscopic sterilization and IUD placement
  • Number of participants with new onset depression as assessed by new prescriptions for antidepressants [12 months post-procedure]: New prescription for anti-depressant medication after hysteroscopic compared to laparoscopic sterilization and IUD placement
  • Number of participants with new onset depression as assessed by new prescriptions for antidepressants [24 months post-procedure]: New prescription for anti-depressant medication after hysteroscopic compared to laparoscopic sterilization and IUD placement
  • Number of participants with new onset depression as assessed by new prescriptions for antidepressants [36 months post-procedure]: New prescription for anti-depressant medication after hysteroscopic compared to laparoscopic sterilization and IUD placement
  • Number of participants with new onset depression as assessed by new prescriptions for antidepressants [48 months post-procedure]: New prescription for anti-depressant medication after hysteroscopic compared to laparoscopic sterilization and IUD placement
  • Number of participants with new onset depression as assessed by new prescriptions for antidepressants [60 months post-procedure]: New prescription for anti-depressant medication after hysteroscopic compared to laparoscopic sterilization and IUD placement
  • Pre-procedure clinical variables associated with procedural complications [Up to 1-year pre-procedure]: Identify sociodemographic and pre-procedure clinical variables which may predict complications following hysteroscopic sterilization compared to laparoscopic sterilization and IUD placement

+Eligibility

Sex: Female, ages: 18 Years to 50 Years, accepts healthy volunteers

Inclusion Criteria:

* Women aged 18-50 years at the time of sterilization procedure
* Claims indicating hysteroscopic or laparoscopic sterilization procedures or IUD placement

Exclusion Criteria:

* Active cancer
* Any conditions that would have excluded the patient for hysteroscopic sterilization
* Any conditions that would have excluded the patient for laparoscopic sterilization

+Locations (1)

FacilityCityCountryStatus
Yale University School of MedicineNew Haven, ConnecticutUnited States

+Publications

  • Results publication: Gariepy AM, Lewis C, Zuckerman D, Tancredi DJ, Murphy E, McDonald-Mosley R, Sonalkar S, Hathaway M, Nunez-Eddy C, Schwarz EB. Comparative effectiveness of hysteroscopic and laparoscopic sterilization for women: a retrospective cohort study. Fertil Steril. 2022 Jun;117(6):1322-1331. doi: 10.1016/j.fertnstert.2022.03.001. Epub 2022 Apr 12. PMID 35428480
  • Results publication: Schwarz EB, Lewis CA, Dove MS, Murphy E, Zuckerman D, Nunez-Eddy C, Tancredi DJ, McDonald-Mosley R, Sonalkar S, Hathaway M, Gariepy AM. Comparative Effectiveness and Safety of Intrauterine Contraception and Tubal Ligation. J Gen Intern Med. 2022 Dec;37(16):4168-4175. doi: 10.1007/s11606-022-07433-4. Epub 2022 Feb 23. PMID 35194746
  • Results publication: Gariepy AM, Lewis C, Zuckerman D, Tancredi DJ, Murphy E, McDonald-Mosley R, Sonalkar S, Hathaway M, Nunez-Eddy C, Schwarz EB. Patient-Centered Safety Outcomes After Hysteroscopic Compared With Laparoscopic Sterilization. Obstet Gynecol. 2022 Mar 1;139(3):423-432. doi: 10.1097/AOG.0000000000004690. PMID 35115444

+Investigators